

Articles and links to studies on psychedelics

9) Bibliography

1. ["A clinical study of LSD treatment in alcoholism"](#) by Arnold Ludwig, Jerome Levine, Louis Stark, and Robert Lazar
2. ["Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study"](#) by Felix Hasler, Ulrike Grimberg, Marco Benz, Theo Huber, and Franz Vollenweider
3. ["Adverse reactions to psychedelic drugs: a review of the literature"](#) by Rick Strassman
4. ["Ayahuasca in adolescence: a neuropsychological assessment"](#) by Evelyn Doering-Silveira, Enrique Lopez, Charles Grob, Marlene Dobkin de Rios, Luisa Alonso, Cristiane Tacla, Itiro Shirakawa, Paulo Bertolucci, and Dartiu Da Silveira
5. ["Ayahuasca in adolescence: a preliminary psychiatric assessment"](#) by Dartiu Da Silveira, Charles Grob, Marlene Dobkin de Rios, Enrique Lopez, Luisa Alonso, Cristiane Tacla, and Evelyn Doering-Silveira
6. ["Ayahuasca in adolescence: qualitative results"](#) by Marlene Dobkin de Rios, Charles Grob, Enrique Lopez, Dartiu Da Silveira, Luisa Alonso, and Evelyn Doering-Silveira
7. ["Daytime ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers"](#) by Manel Barbanoj, Jordi Riba, S. Clos, S. Giménez, E. Grasa, and S. Romero
8. ["Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans"](#) by Rick Strassman, Clifford Qualls, and Laura Berg
9. ["Do hallucinogens cause residual neuropsychological toxicity?"](#) by John Halpern and Harrison Pope
10. ["Dose-response study of N,N-dimethyltryptamine in humans: subjective effects and preliminary results of a new rating scale"](#) by Rick Strassman, Clifford Qualls, Eberhard Uhlenhuth, and Robert Kellner
11. ["Dr. Leary's Concord Prison Experiment: a 34-year follow-up study"](#) by Rick Doblin
12. ["Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively"](#) by Jordi Riba, Antoni Rodríguez-Fornells, and Manel Barbanoj
13. ["Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament"](#) by John Halpern, Andrea Sherwood, Torsten Passie, Kimberly Blackwell, and A. James Rutenber

14. ["Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin"](#) by Katherine MacLean, Jeannie-Marie Leoutsakos, Matthew Johnson, and Roland Griffiths
15. ["Flashback: psychiatric experimentation with LSD in historical perspective"](#) by Erika Dyck
16. ["Hallucinogenic drugs in psychiatric research and treatment: perspectives and prospects"](#) by Rick Strassman
17. ["Hallucinogens"](#) by David Nichols
18. ["Hallucinogens and related compounds"](#) by Charles Grob and Marlene Dobkin de Rios
19. ["‘Hitting highs at rock bottom’: LSD treatment for alcoholism"](#) by Erika Dyck
20. ["Human hallucinogen research: guidelines for safety"](#) by Matthew Johnson, William Richards, and Roland Griffiths
21. ["Lysergic acid diethylamide \(LSD\) for alcoholism: meta-analysis of randomized controlled trials"](#) by Teri Krebs and Pål-Ørjan Johansen
22. ["Lysergic acid diethylamide: side effects and complications"](#) by Sidney Cohen
23. ["Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness"](#) by Katherine MacLean, Matthew Johnson, and Roland Griffiths
24. ["Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later"](#) by Roland Griffiths, William Richards, Mathew Johnson, Una McCann, and Robert Jesse
25. ["Neural correlates of the LSD experience revealed by multimodal neuroimaging"](#) by Robin Carhart-Harris, Suresh Muthukumaraswamy, Leor Roseman, Mendel Kaelen, Wouter Droog, Kevin Murphy, Enzo Tagliazucchi, Eduardo Schenberg, Timothy Nest, Csaba Orban, Robert Leech, Luke Williams, Tim Williams, Mark Bolstridge, Ben Sessa, John McGonigle, Martin Sereno, David Nichols, Peter Hellyer, Peter Hobden, John Evans, Krish Singh, Richard Wise, H. Valerie Curran, Amanda Feilding, and David Nutt
26. ["Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine \(MDE\) and d-methamphetamine in healthy volunteers: a double-blind, placebo-controlled PET study with \[¹⁸F\]FDG"](#) by Euphrosyne Gouzoulis-Mayfrank, Mathias Schreckenberger, Osama Sabri, Christoph Arning, Bernhard Thelen, Manfred Spitzer, Karl-Artur Kovar, Leopold Hermlle, Udalrich Büll, and Henning Sass
27. ["Neurotoxicity and LSD treatment: a follow-up study of 151 patients in Denmark"](#) by Jens Knud Larsen
28. ["Pahnke’s ‘Good Friday Experiment’: a long-term follow-up and methodological critique"](#) by Rick Doblin

29. ["Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer"](#) by Charles Grob, Alicia Danforth, Gurpreet Chopra, Marycie Hagerty, Charles McKay, Adam Halberstadt, and George Greer
30. ["Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction"](#) by Matthew Johnson, Albert Garcia-Romeu, Mary Cosimano, and Roland Griffiths
31. ["Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis"](#) by Franz Vollenweider, Klaus Leenders, Christian Scharfetter, Peter Maguire, Otto Stadelmann, Jules Angst
32. ["Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study"](#) by Michael Bogenschutz, Alyssa Forcehimes, Jessica Pommy, Claire Wilcox, PCR Barbosa, and Rick Strassman
33. ["Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance"](#) by Roland Griffiths, William Richards, Una McCann, and Robert Jesse
34. ["Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial"](#) by Roland Griffiths, Matthew Johnson, Michael Carducci, Annie Umbricht, William Richards, Brian Richards, Mary Cosimano, and Margaret Klinedinst
35. ["Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects"](#) by Roland Griffiths, Matthew Johnson, William Richards, Brian Richards, Una McCann, and Robert Jesse
36. ["Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction"](#) by Albert Garcia-Romeu, Roland Griffiths, and Matthew Johnson
37. ["Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans"](#) by Olivia Carter, Felix Hasler, John Pettigrew, Guy Wallis, Guang Liu, Franz Vollenweider
38. ["Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study"](#) by Robin Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James Rickard, Ben Forbes, Amanda Feilding, David Taylor, Steve Pilling, Valerie Curran, and David Nutt
39. ["Psychedelic drug assisted psychotherapy in patients with terminal cancer"](#) by Albert Kurland, Stanislav Grof, Walter Pahnke, and Louis Goodman
40. ["Psychological and cognitive effects of long-term peyote use among Native Americans"](#) by John Halpern, Andrea Sherwood, James Hudson, Deborah Yurgelun-Todd, and Harrison Pope
41. ["Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine \(MDE\), psilocybin and d-methamphetamine in healthy volunteers: results of an experimental double-blind placebo-controlled study"](#) by Euphrosyne Gouzoulis-Mayfrank, Bernhard Thelen, E. Habermeyer, H.J. Kunert, Karl-Artur Kovar, H. Lindenblatt, Leopold Hermle, Manfred Spitzer, and Henning Sass

42. ["Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial"](#) by Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah Mennenga, Alexander Belsler, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, and Brian Schmidt
43. ["Reflections on the Concord Prison Project and the follow-up study"](#) by Ralph Metzner
44. ["Report on psychoactive drug use among adolescents using ayahuasca within a religious context"](#) by Evelyn Doering-Silveira, Charles Grob, Marlene Dobkin de Rios, Enrique Lopez, Luisa Alonso, Cristiane Tacla, and Dartiu Da Silveira
45. ["Response of cluster headache to psilocybin and LSD"](#) by R. Andrew Sewell, John Halpern, and Harrison Pope
46. ["Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder"](#) by Francisco Moreno, Christopher Wiegand, E. Keolani Taitano, and Pedro Delgado
47. ["Serotonin research: contributions to understanding psychoses"](#) by Mark Geyer and Franz Vollenweider
48. ["The behavioral pharmacology of hallucinogens"](#) by William Fantegrossi, Kevin Murnane, and Chad Reissig
49. ["The effects of the preferential 5-HT_{2A} agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval"](#) by Franz Vollenweider, Philipp Csomor, Bernhard Knappe, Mark Geyer, and Boris Quednow
50. ["The pharmacology of psilocybin"](#) by Torsten Passie, Juergen Seifert, Udo Schneider, and Hinderk Emrich
51. ["The pharmacology of lysergic acid diethylamide: a review"](#) by Torsten Passie, John Halpern, Dirk Stichtenoth, Hinderk Emrich, and Annelie Hintzen
52. ["Treatment of alcoholism using psychedelic drugs: a review of the program of research"](#) by Mariavittoria Mangini
53. ["Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer"](#) by Charles Grob, Anthony Bossis, and Roland Griffiths